复星医药(02196.HK)：控股子公司丁二酸复瑞替尼胶囊获临床试验批准

智通财经2025-09-08

【复星医药(02196.HK)：控股子公司丁二酸复瑞替尼胶囊获临床试验批准】智通财经APP讯，复星医药(02196.HK)发布公告，公司控股子公司复星万邦(江苏)医药集团有限公司(“复星万邦”)于近期收到国家药品监督管理局(以下简称“国家药监局”)关于同意丁二酸复瑞替尼胶囊(项目代号： SAF-189，申请注册分类：化药1类;以下简称“该新药”)用于间变性淋巴瘤激酶(ALK)阳性或者c-ros...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2565683688?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-08 18:29","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2565683688","market":"hk","top_or_hot":-1,"title":"复星医药(02196.HK)：控股子公司丁二酸复瑞替尼胶囊获临床试验批准","media":"智通财经","content":"<div>\n<p>【复星医药(02196.HK)：控股子公司丁二酸复瑞替尼胶囊获临床试验批准】智通财经APP讯，复星医药(02196.HK)发布公告，公司控股子公司复星万邦(江苏)医药集团有限公司(“复星万邦”)于近期收到国家药品监督管理局(以下简称“国家药监局”)关于同意丁二酸复瑞替尼胶囊(项目代号： \n\nSAF-189，申请注册分类：化药1类;以下简称“该新药”)用于间变性淋巴瘤激酶(ALK)阳性或者c-ros...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复星医药(02196.HK)：控股子公司丁二酸复瑞替尼胶囊获临床试验批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复星医药(02196.HK)：控股子公司丁二酸复瑞替尼胶囊获临床试验批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-08 18:29 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=ganggu><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【复星医药(02196.HK)：控股子公司丁二酸复瑞替尼胶囊获临床试验批准】智通财经APP讯，复星医药(02196.HK)发布公告，公司控股子公司复星万邦(江苏)医药集团有限公司(“复星万邦”)于近期收到国家药品监督管理局(以下简称“国家药监局”)关于同意丁二酸复瑞替尼胶囊(项目代号： \n\nSAF-189，申请注册分类：化药1类;以下简称“该新药”)用于间变性淋巴瘤激酶(ALK)阳性或者c-ros...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2565683688","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565683688","pubTimestamp":1757327384,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【复星医药(02196.HK)：控股子公司丁二酸复瑞替尼胶囊获临床试验批准】智通财经APP讯，复星医药(02196.HK)发布公告，公司控股子公司复星万邦(江苏)医药集团有限公司(“复星万邦”)于近期","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","BK0188":"融资融券","BK4588":"碎股","BK4008":"航空公司","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","BK0012":"证金概念","BK0187":"一线龙头","BK4146":"鞋类","BK0028":"国家队","BK1191":"制药","BK4561":"索罗斯持仓","BK1593":"医美概念股","BK0175":"白马股","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","BK0060":"抗癌","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","BK4581":"高盛持仓","ALK.AU":"ALKANE RESOURCES LTD","BK1515":"抗疫概念","BK4500":"航空公司","BK4534":"瑞士信贷持仓","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","BK4585":"ETF&股票定投概念","BK0196":"行业龙头","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0823411888.USD":"法巴消费创新基金 Cap","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK0239":"医药制造","BK7104":"黄金","BK4566":"资本集团","BK4558":"双十一","BK0096":"民营医院","NKE":"耐克","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU1303367103.USD":"摩根大通多经理另类基金 A (acc)","ALK":"阿拉斯加航空集团有限公司","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","02196":"复星医药","LU2098885051.SGD":"JPMorgan Funds - Multi-Manager Alternatives A (acc) SGD","BK7506":"金矿股","BK0183":"MSCI概念"},"translate_title":"Fosun Pharma (02196. HK): The holding subsidiary Foritinib Succinate Capsules was approved for clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"NKE":1,"02196":1,"ALK":1,"ALK.AU":1},"content_text":"【复星医药(02196.HK)：控股子公司丁二酸复瑞替尼胶囊获临床试验批准】智通财经APP讯，复星医药(02196.HK)发布公告，公司控股子公司复星万邦(江苏)医药集团有限公司(“复星万邦”)于近期收到国家药品监督管理局(以下简称“国家药监局”)关于同意丁二酸复瑞替尼胶囊(项目代号： \n\nSAF-189，申请注册分类：化药1类;以下简称“该新药”)用于间变性淋巴瘤激酶(ALK)阳性或者c-ros肉瘤致癌因子-受体酪氨酸激酶(ROS1)阳性的IB期至ⅢA期非小细胞肺癌患者肿瘤根治性切除术后的辅助治疗开展临床试验的批准。复星万邦拟于条件具备后于中国境内(不包括港澳台地区，下同)开展该新药的Ⅲ期临床试验。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2565683688","isCrawlerRequest":true}